The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course
- PMID:2597989
- DOI: 10.1093/brain/112.6.1419
The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course
Abstract
Controversy exists regarding the predictive value of the early clinical course of multiple sclerosis (MS). Three parameters often considered are the attack rate, the first interattack interval and the rate at which disability develops in the early years of the disease. We have recorded the time to reach successive levels of disability defined by the Kurtzke Disability Status Scale (DSS) in 1,099 MS patients followed at University Hospital, London, Canada between 1972 and 1984. Our population is particularly suitable because of its size, the high degree of ascertainment of cases in the community, and the regular follow-up provided. Life table analysis was used to compare survival in patients stratified according to the above three parameters using DSS 6 as end point. Significant differences were evident in the survival distributions. Despite the extensive interindividual variation in the rate at which disability developed, the early course of MS may be useful in determining the relative risk of rapid progression.
Similar articles
- The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC.Weinshenker BG, et al.Brain. 1989 Feb;112 ( Pt 1):133-46. doi: 10.1093/brain/112.1.133.Brain. 1989.PMID:2917275
- The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.Cottrell DA, Kremenchutzky M, Rice GP, Koopman WJ, Hader W, Baskerville J, Ebers GC.Cottrell DA, et al.Brain. 1999 Apr;122 ( Pt 4):625-39. doi: 10.1093/brain/122.4.625.Brain. 1999.PMID:10219776
- The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC.Kremenchutzky M, et al.Brain. 2006 Mar;129(Pt 3):584-94. doi: 10.1093/brain/awh721. Epub 2006 Jan 9.Brain. 2006.PMID:16401620
- The natural history of multiple sclerosis.Weinshenker BG, Ebers GC.Weinshenker BG, et al.Can J Neurol Sci. 1987 Aug;14(3):255-61. doi: 10.1017/s0317167100026573.Can J Neurol Sci. 1987.PMID:3311324Review.
- The natural history of multiple sclerosis: update 1998.Weinshenker BG.Weinshenker BG.Semin Neurol. 1998;18(3):301-7. doi: 10.1055/s-2008-1040881.Semin Neurol. 1998.PMID:9817534Review.
Cited by
- Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study.Bsteh G, Ehling R, Lutterotti A, Hegen H, Di Pauli F, Auer M, Deisenhammer F, Reindl M, Berger T.Bsteh G, et al.PLoS One. 2016 Jul 8;11(7):e0158978. doi: 10.1371/journal.pone.0158978. eCollection 2016.PLoS One. 2016.PMID:27391947Free PMC article.
- Prognostic criteria in an epidemiological group of patients with multiple sclerosis: an exploratory study.Lauer K, Firnhaber W.Lauer K, et al.J Neurol. 1992 Feb;239(2):93-7. doi: 10.1007/BF00862981.J Neurol. 1992.PMID:1552310
- Modeling the heterogeneity of multiple sclerosis in animals.Simmons SB, Pierson ER, Lee SY, Goverman JM.Simmons SB, et al.Trends Immunol. 2013 Aug;34(8):410-22. doi: 10.1016/j.it.2013.04.006. Epub 2013 May 21.Trends Immunol. 2013.PMID:23707039Free PMC article.Review.
- Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE).Tuncer MA, Kürtüncü M, Terzi M, Uygunoğlu U, Göncüoğlu C, Yüceyar AN, Ekmekçi Ö, Türkoğlu R, Soysal A, Köseoğlu M, Boz C, Beckmann Y, Turan ÖF, Demirkıran DM, Akman FG, Altunrende B, Cantürk İA, Birday E, Özcan A, Kamişli Ö, Özen NPA, Çelik RGG, Balcı FB, Efendi H, Sarıkaya C, Akçalı A, Toprak MK, Kabay SC, Kızılay F, Sevim MS, Gazaloğlu GB, Demir CF, Balgetir F, Kıylıoğlu N, Sarıahmetoğlu H, Ölmez Ç, Mavi K, Yüksel S, Işık N, Saip S, Karabudak R, Siva A, Eraksoy M.Tuncer MA, et al.Turk J Med Sci. 2023 Feb;53(1):323-332. doi: 10.55730/1300-0144.5588. Epub 2023 Feb 22.Turk J Med Sci. 2023.PMID:36945929Free PMC article.
- Disease-modifying Therapies for Multiple Sclerosis.Corboy JR, Goodin DS, Frohman EM.Corboy JR, et al.Curr Treat Options Neurol. 2003 Jan;5(1):35-54. doi: 10.1007/s11940-003-0021-0.Curr Treat Options Neurol. 2003.PMID:12521562
Publication types
MeSH terms
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical